Transplacental Transfer of Maternal Respiratory Syncytial Virus (RSV) Antibody and Protection against RSV Disease in Infants in Rural Nepal
Pneumonia is the leading cause of childhood deaths in developing countries. Respiratory syncytial virus (RSV) is the most important cause of viral pneumonia in infants worldwide, with an estimated global burden of 64 million infections and 160,000 deaths annually. There are limited pharmacologic therapies and no licensed vaccine against RSV [1]. Advances in immunology and virology have accelerated the RSV vaccine field significantly in the past decade, and the World Health Organization has estimated that an RSV vaccine will be in clinical use within the next 5-10 years [2].
Source: Journal of Clinical Virology - Category: Virology Authors: Helen Y. Chu, James Tielsch, Joanne Katz, Amalia S. Magaret, Khatry Subarna, Stephen C. LeClerq, Laxman Shrestha, Jane Kuypers, Mark C. Steinhoff, Janet A. Englund Tags: Full length article Source Type: research
More News: Allergy & Immunology | International Medicine & Public Health | Nepal Health | Pneomococcal Vaccine | Pneumonia | Respiratory Medicine | Rural Health | Vaccines | Virology | WHO